TY  - CHAP
M1  - Book, Section
TI  - Rosacea
A1  - Zeichner, Joshua
A1  - Mitchell, Krystal
A2  - Baumann, Leslie S.
A2  - Rieder, Evan A.
A2  - Sun, Mary D.
Y1  - 2022
N1  - 
T2  - Baumann’s Cosmetic Dermatology, 3e
AB  - SUMMARY  POINTSWhat’s  newThe  potential  role  of  probiotics  in  rosacea  given  the  innate/adaptive  immunity  dysregulation  and  the  contribution  of  commensal  and  pathogenic  bacteria.Transient  receptor  potential  channels,  vanilloid  (TRPV)  and  ankyrin  (TRPA),  may  contribute  to  the  role  of  flushing  and  burning  in  rosacea.Zonulin,  a  human  protein  that  regulates  intestinal  permeability,  is  significantly  higher  in  patients  with  rosacea.Topical  minocycline  foam  (Zilxi)  has  recently  received  FDA  approval  for  the  treatment  of  rosacea.What’s  importantTreatment  of  rosacea  focuses  on  patient  education,  skincare,  and  pharmacologic/procedural  interventions.Distinguishing  rosacea  from  other  conditions  and  initiation  of  early  treatment  when  a  patient  reports  flushing  and  burning.Treatment  of  rosacea  involves  addressing  both  background  facial  redness  and  inflammatory  lesions.What  We  Don’t  KnowThe  pathogenesis  of  rosacea  has  yet  to  be  fully  elucidated  and  it  is  unclear  whether  the  four  rosacea  subtypes  are  truly  variants  of  the  same  condition.The  mechanism  by  which  TLR2  is  activated  by  Demodex  mites.The  potential  virulence  factors  of  S.  epidermidis  in  patients  with  rosacea.What’s  comingThe  use  of  cromolyn,  a  mast  cell  stabilizer,  in  patients  with  rosacea.The  use  of  protease  serine  inhibitors  to  prevent  the  formation  of  the  abnormal  cathelicidin  (LL-37)  in  patients  with  rosacea.  
SN  - 
PB  - McGraw Hill LLC
CY  - New York, NY
Y2  - 2024/04/19
UR  - dermatology.mhmedical.com/content.aspx?aid=1197533745
ER  -